References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Frank S, Testa CM, Stamler D, et al; Huntington Study Group ARC-HD Investigators. Long-term efficacy and safety of deutetrabenazine for chorea in Huntington's disease: results from the ARC-HD open-label study. Poster presented at: the 27th Annual Meeting of the Huntington Study Group (HSG); October 29-31, 2020. 3. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed January 28, 2022. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf 4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
Treating Huntington's disease chorea with AUSTEDO
In a 12 week clinical study,
AUSTEDO (deutetrabenazine) tablets significantly reduced Huntington's disease (HD) chorea1
People taking AUSTEDO saw >2x reduction in HD chorea movements vs placebo*

*4.4-point improvement in people taking AUSTEDO vs 1.9 in people taking placebo based on Total Maximal Chorea (TMC) score. The TMC score is used to measure HD chorea movements in the face, mouth, trunk, both arms, and both legs.
An open label study† showed
symptom relief was sustained for
~3 YEARS2‡
†An open label study is a drug trial in which all participants are aware of the drug being tested.
‡Mean TMC score changed minimally from Week 8 to Week 132 (or end of treatment).
People on AUSTEDO reported improvement in their ability to perform daily activities like3,4:
- Climbing stairs
- Moderate to vigorous activities
- Lifting/carrying groceries
- Bathing
- Walking
- Dressing
- Bending, kneeling, or stooping
People taking AUSTEDO achieved greater improvement in the SF-36§ Physical Functioning Score at 12 weeks vs placebo4
§SF-36=Short form 36 item survey assessing health-related quality of life.
Both patients and doctors rated overall HD symptoms as "much improved" or "very much improved" at 12 weeks with AUSTEDO.1,4
51% of people on AUSTEDO saw treatment success vs 20% on placebo1¶
Very much improved/Much improved
51%
of people on AUSTEDO saw treatment success1¶
vs placebo
20%
42% of doctors saw treatment success vs 13% on placebo1¶
Very much improved/Much improved
42%
of doctors saw treatment success1¶
vs placebo
13%
¶Treatment success is measured by perceived improvement in TMC score.
AUSTEDO does not cure the cause of the involuntary movements and it does not treat the other symptoms of HD, such as problems with thinking or emotions.
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
You are about to leave this site
You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.